Asset Publisher

Draft Genetic Testing Policies

Effective March 1, 2020, Blue Cross and Blue Shield of Florida implemented genetic testing policies in coordination with Carelon Medical Benefits Management.

Carelon is our business associate and an independent company that provides diagnostic testing, information and services. Carelon has agreed to follow our privacy and security policies regarding the confidentiality and protection of personal health information.

Note: Coverage is subject to the member's specific benefits. Group-specific policies will supersede these policies when applicable. Please refer to the member's benefit plan.

Draft Genetic Testing Policies

Effective June 30, 2024, the following updates apply to Carelon's Genetic Testing Clinical Appropriateness Guidelines. As part of the Carelon guideline annual review process, these updates focus on advancing efforts to drive clinically appropriate, safe and affordable healthcare services.

Summary of Changes to Carelon Genetic Testing Clinical Appropriateness Guidelines Effective June 30, 2024

To continue to the Carelon website to view genetic testing policies, click "Accept" below.


Comment on Draft Policies

To ensure that the development of medical policies occurs through an open, collaborative process, we welcome comments about medical policies that are in the draft stage. 

Participating providers are invited to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration.

Comments are accepted for 45 days from the posting date listed on the draft

Make sure your voice is heard by providing feedback directly to us:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202

Fax: 205-220-0878